Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

Imagine this: it's a Friday morning in London, and as you stroll down the streets, you're suddenly greeted by an incredible sight. A McLaren P1 zooms past, and behind the wheel is none other than ...

辉瑞的自免业务虽然仍在TOP10行列，但似乎呈现逐年萎缩的趋势。JAK抑制剂Xeljanz（托法替布）难逃专利悬崖的冲击，2024年销售额为11.68亿美元，同比下降31%。Enbrel（依那西普）由安进和辉瑞共同开发，其收入大头由安进拿走，辉瑞20 ...

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments. The transaction adds a pipeline of early-stage drug ...

And this is Roopal. I'll cover the NLRX question. This is our asset from Landos. We had observed very early data, I would say Phase 1b, in ulcerative colitis, and that looked good, but it was a ...

A "highly vocal minority" stuck in the past is holding back the development of Canberra, according to one of the city's ...

As aquaculture takes on a major role in global seafood production, the industry has encountered several hurdles, notably in disease management and overharvesting in natural habitats challenges.

当地时间2月12日，艾伯维（NYSE：ABBV）与Xilio Therapeutics（NASDAQ：XLO）宣布达成一项合作和选择性许可协议，双方将利用Xilio的专有技术，共同开发新型肿瘤激活、基于抗体的免疫疗法，其中包括掩蔽型T细胞接合器（TCE）。

包括收购Nimble获得其核心资产口服多肽IL-23抑制剂、17.1亿美元引进明济生物靶向TL1A单抗、收购Landos Biopharma获得针对NLRX1和PLXDC2通路的多个创新项目等。

AbbVie's Q4 EPS of $2.16 beat the forecast by $0.10. Revenue for the quarter was $15.1 billion, exceeding expectations. The stock price increased by 6.82% following the earnings release. Full-year ...